Vect-Horus has a clinical-phase solution to a key drug development challenge: crossing the blood–brain barrier (BBB). By targeting receptors on the barrier, Vect-Horus is empowering partners such as ...

Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it is ...

This publication provides an overview of central nervous system (CNS) radiotracer development, discussing different aspects and stages of development. Non-invasive neuroimaging with radiotracers can ...

HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments ...

SAN FRANCISCO, April 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat ...

Cold Spring Harbor Laboratory postdoc Stan Kerstjens and colleagues have devised a new theory for how the brain organizes ...